Boehringer walks away from CureVac deal
Setback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 287 entries already.
Entries by Uta Mommert
New vaccine trial targets Covid variants
Vaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001.
Protein may help control cancer cells
The protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find.
Sanofi snaps up mRNA partner for US$3.2bn
Sanofi further launches into the messenger RNA space with US$3.2bn buy-out of mRNA pioneer Translate Bio.
Panakès expands into biotech with €150m fund
Italian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
€26m financing for ISA Pharmaceuticals
Dutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.
Novo Nordisk invests in amyloidosis pipeline
Danish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Sanofi invests heavily in multiple myeloma pipeline
Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
NFL Biosciences goes public, raises €5m
French biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.
Promethera bags €20m for liver failure treatment
With a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure.